1365564-13-1

Basic information

• Product Name: C₂₂H₂₉NO₂
• Synonyms: C₂₂H₂₉NO₂
• CAS NO: 1365564-13-1
• Molecular Weight: 339.478
• Mol File: 1365564-13-1.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: C₂₂H₂₉NO₂(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₂H₂₉NO₂(1365564-13-1)
• EPA Substance Registry System: C₂₂H₂₉NO₂(1365564-13-1)

Safety Data

• Hazardous Substances Data: 1365564-13-1(Hazardous Substances Data)

Upstream product

• 1202778-95-7 cyano-di(3-phenyl-prop-1-yl)acetic acid methyl ester 
• 1025483-41-3 methyl 2-cyano-5-phenylpentanoate 
• 637-59-2 1-Bromo-3-phenylpropane 

Downstream Products

• 1202779-20-1 C₂₆H₃₅NO₄ 

Relevant articles and documents

Synthesis of anticancer heptapeptides containing a unique lipophilic β2,2-amino acid building block

We report a series of synthetic anticancer heptapeptides (H-KKWβ2,2WKK-NH2) containing eight different central lipophilic β2,2-amino acid building blocks, which have demonstrated high efficiency when used as scaffolds in small cationic antimicrobial peptides and peptidomimetics. The most potent peptides in the present study had IC50 values of 9-23μm against human Burkitt's lymphoma and murine B-cell lymphoma and were all nonhaemolytic (EC50>200μm). The most promising peptide 10e also demonstrated low toxicity against human embryonic lung fibroblast cells and peripheral blood mononuclear cells and exceptional proteolytic stability.

Antimicrobial activity of small β-peptidomimetics based on the pharmacophore model of short cationic antimicrobial peptides

We have synthesized a series of small β-peptidomimetics (Mw 2,2-amino acid coupled to a C-terminal L-arginine amide residue. By varying the lipophilic side-chains of the β2,2-amino acids, we obtained a series of highly potent β-peptidomimetics with high enzymatic stability against α-chymotrypsin and a general low toxicity against human erythrocytes. The most potent β-peptidomimetics displayed minimal inhibitory concentrations of 2.1-7.2 μM against Staphylococcus aureus, methicillin resistant Staphylococcus aureus (MRSA), methicillin resistant Staphylococcus epidermidis (MRSE), and Escherichia coli. Small amphipathic β-peptidomimetics may be a promising class of antimicrobial agents by means of having a similar range of potency and selectivity as larger cationic antimicrobial peptides in addition to improved enzymatic stability and lower costs of production.